Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 278,657 shares of the biopharmaceutical company’s stock after selling 32,147 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.21% of Alnylam Pharmaceuticals worth $111,510,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ALNY. Groupama Asset Managment increased its holdings in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after purchasing an additional 2,483,697 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after buying an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $369,943,000. Holocene Advisors LP acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $194,616,000. Finally, AQR Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 295.2% in the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after buying an additional 555,759 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the transaction, the chief executive officer owned 98,628 shares of the company’s stock, valued at $32,315,464.20. This trade represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Pushkal Garg sold 1,775 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the sale, the executive vice president directly owned 23,406 shares in the company, valued at approximately $7,483,834.44. This trade represents a 7.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,923 shares of company stock valued at $18,072,087 over the last quarter. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ALNY shares. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $473.87.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $330.71 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a fifty day moving average price of $329.31 and a two-hundred day moving average price of $397.65. The company has a market cap of $43.86 billion, a PE ratio of 193.40 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period last year, the company posted ($0.65) earnings per share. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.